LeMaitre Vascular, Inc. (NASDAQ:LMAT) Short Interest Update

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 1,210,000 shares, a growth of 37.5% from the December 31st total of 880,000 shares. Based on an average daily volume of 157,900 shares, the short-interest ratio is presently 7.7 days. Currently, 5.9% of the shares of the stock are sold short.

LeMaitre Vascular Stock Up 1.8 %

LMAT stock traded up $1.75 during midday trading on Tuesday, reaching $97.18. The company's stock had a trading volume of 78,092 shares, compared to its average volume of 144,932. LeMaitre Vascular has a 52 week low of $57.60 and a 52 week high of $109.58. The stock has a market cap of $2.18 billion, a PE ratio of 53.12, a price-to-earnings-growth ratio of 2.13 and a beta of 0.96. The business's 50-day simple moving average is $97.41 and its 200-day simple moving average is $92.94.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of the company's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now directly owns 2,278 shares of the company's stock, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.79% of the company's stock.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. New York State Teachers Retirement System boosted its stake in LeMaitre Vascular by 1.2% in the fourth quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock valued at $755,000 after acquiring an additional 100 shares during the last quarter. Shaker Investments LLC OH boosted its stake in LeMaitre Vascular by 0.8% in the fourth quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock valued at $1,285,000 after acquiring an additional 112 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in LeMaitre Vascular by 6.0% in the fourth quarter. Sanctuary Advisors LLC now owns 2,065 shares of the medical instruments supplier's stock worth $207,000 after purchasing an additional 117 shares during the period. Glenmede Trust Co. NA raised its holdings in LeMaitre Vascular by 1.3% in the third quarter. Glenmede Trust Co. NA now owns 10,512 shares of the medical instruments supplier's stock worth $976,000 after purchasing an additional 136 shares during the period. Finally, Summit Global Investments raised its holdings in LeMaitre Vascular by 2.4% in the third quarter. Summit Global Investments now owns 6,192 shares of the medical instruments supplier's stock worth $575,000 after purchasing an additional 146 shares during the period. 84.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LMAT. StockNews.com cut shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research note on Friday, December 13th. Oppenheimer reaffirmed an "outperform" rating and set a $93.00 price objective (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They set a "neutral" rating and a $96.00 price target on the stock. Finally, Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an "outperform" rating in a research note on Friday, November 1st. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.